Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
SNGX
$1.18
$
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Next Earnings
2026-02-25
Beta
2.006
Average Volume
Market Cap
Last Dividend
CIK
0000812796
ISIN
US8342236044
CUSIP
834223604
CEO
Christopher J. Schaber
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
14
IPO Date
1994-04-04
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Soligenix to Present at BIO Investment & Growth Summit | PRINCETON, N.J., Feb. 24, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Christopher J. | PRNewsWire | 2026-02-24 07:30:00 |
| Soligenix Details Recent Progress and Upcoming Milestones | PRINCETON, N.J., Feb. 12, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. | PRNewsWire | 2026-02-12 07:30:00 |
| Short Interest in Soligenix Inc. (NASDAQ:SNGX) Decreases By 12.5% | Soligenix Inc. (NASDAQ: SNGX - Get Free Report) was the target of a significant drop in short interest in the month of January. As of January 15th, there was short interest totaling 454,993 shares, a drop of 12.5% from the December 31st total of 519,758 shares. Approximately 4.7% of the company's stock are sold short. Based | Defense World | 2026-02-05 01:20:43 |
| Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) | Study results support advancing SGX945 in this difficult-to-treat orphan disease Results suggest potential durability of response for maintenance therapy PRINCETON, N.J. , Dec. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the results from its Phase 2a proof of concept study evaluating SGX945 (dusquetide) in the treatment of Behçet's Disease have been published in Rheumatology (Oxford), in an article entitled "Results from a Pilot Study of Dusquetide for the Treatment of Aphthous Ulcers Associated with Behçet Syndrome". | PRNewsWire | 2025-12-18 07:30:00 |
| Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel | Soligenix, Inc. (NASDAQ: SNGX) on Wednesday announced extended results of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for mild-to-moderate psoriasis. | Benzinga | 2025-12-17 13:23:00 |
| Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis | Optimized Gel Formulation Demonstrates Clinical Success in Third Cohort of Patients PRINCETON, N.J. , Dec. 17, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today extended results of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis. | PRNewsWire | 2025-12-17 07:30:00 |
| Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space | NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- via BioMedWire: — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire ("BMW"), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork ), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. | GlobeNewsWire | 2025-12-03 08:30:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| 8-K | 2026-02-12 | 2026-02-12 | View Filing |
| 424B5 | 2026-01-23 | 2026-01-23 | View Filing |
| 8-K | 2026-01-23 | 2026-01-23 | View Filing |
| 4 | 2025-12-12 | 2025-12-12 | View Filing |
| 4 | 2025-12-12 | 2025-12-12 | View Filing |
| 4 | 2025-12-12 | 2025-12-12 | View Filing |
| 4 | 2025-12-12 | 2025-12-12 | View Filing |
| 8-K | 2025-11-18 | 2025-11-18 | View Filing |
| SC 13G | 2025-11-14 | 2025-11-14 | View Filing |
| 424B3 | 2025-11-07 | 2025-11-07 | View Filing |
| 424B3 | 2025-11-07 | 2025-11-07 | View Filing |
| 424B3 | 2025-11-07 | 2025-11-07 | View Filing |
| 10-Q | 2025-11-07 | 2025-11-07 | View Filing |
| 4 | 2025-10-03 | 2025-10-03 | View Filing |
| SC 13G | 2025-10-01 | 2025-10-01 | View Filing |
| 8-K | 2025-09-29 | 2025-09-29 | View Filing |
| 424B4 | 2025-09-26 | 2025-09-26 | View Filing |
| EFFECT | 2025-09-26 | 2025-09-26 | View Filing |
| S-1 | 2025-09-19 | 2025-09-19 | View Filing |
| 8-K | 2025-08-18 | 2025-08-18 | View Filing |
| 424B3 | 2025-08-15 | 2025-08-15 | View Filing |
| 8-K | 2025-08-15 | 2025-08-15 | View Filing |
| 424B3 | 2025-08-15 | 2025-08-15 | View Filing |
| 424B3 | 2025-08-15 | 2025-08-15 | View Filing |
| 10-Q | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K | 2025-07-31 | 2025-07-31 | View Filing |
| 4 | 2025-06-20 | 2025-06-20 | View Filing |
| 4 | 2025-06-20 | 2025-06-20 | View Filing |
| 4 | 2025-06-20 | 2025-06-20 | View Filing |
| 4 | 2025-06-20 | 2025-06-20 | View Filing |
| S-8 | 2025-06-20 | 2025-06-20 | View Filing |
| 8-K | 2025-06-20 | 2025-06-20 | View Filing |
| 10-Q | 2025-05-09 | 2025-05-09 | View Filing |
| ARS | 2025-05-05 | 2025-05-05 | View Filing |
| DEFA14A | 2025-05-05 | 2025-05-05 | View Filing |
| DEF 14A | 2025-05-05 | 2025-05-05 | View Filing |
| 8-K | 2025-03-28 | 2025-03-28 | View Filing |
| EFFECT | 2025-03-27 | 2025-03-27 | View Filing |
| EFFECT | 2025-03-27 | 2025-03-27 | View Filing |
| EFFECT | 2025-03-27 | 2025-03-27 | View Filing |
| POS AM | 2025-03-21 | 2025-03-21 | View Filing |
| POS AM | 2025-03-21 | 2025-03-21 | View Filing |
| POS AM | 2025-03-21 | 2025-03-21 | View Filing |
| 10-K | 2025-03-21 | 2025-03-21 | View Filing |
| 8-K | 2025-02-10 | 2025-02-10 | View Filing |
| 4 | 2024-12-13 | 2024-12-13 | View Filing |
| 4 | 2024-12-13 | 2024-12-13 | View Filing |
| 4 | 2024-12-13 | 2024-12-13 | View Filing |
| 4 | 2024-12-13 | 2024-12-13 | View Filing |
| 4 | 2024-12-13 | 2024-12-13 | View Filing |
| 4 | 2024-12-13 | 2024-12-13 | View Filing |
| 4 | 2024-12-13 | 2024-12-13 | View Filing |
| 4 | 2024-12-13 | 2024-12-13 | View Filing |
| 424B3 | 2024-11-08 | 2024-11-08 | View Filing |
| 424B3 | 2024-11-08 | 2024-11-08 | View Filing |
| 424B3 | 2024-11-08 | 2024-11-08 | View Filing |
| 10-Q | 2024-11-08 | 2024-11-08 | View Filing |
| 8-K | 2024-10-11 | 2024-10-11 | View Filing |
| 424B5 | 2024-08-16 | 2024-08-16 | View Filing |
| 8-K | 2024-08-16 | 2024-08-16 | View Filing |
| 424B3 | 2024-08-09 | 2024-08-09 | View Filing |
| 424B3 | 2024-08-09 | 2024-08-09 | View Filing |
| 10-Q | 2024-08-09 | 2024-08-09 | View Filing |
| EFFECT | 2024-08-05 | 2024-08-05 | View Filing |
| 8-K | 2024-07-25 | 2024-07-25 | View Filing |
| S-1 | 2024-07-24 | 2024-07-24 | View Filing |
| 8-K | 2024-07-09 | 2024-07-09 | View Filing |
| 8-K | 2024-05-31 | 2024-05-31 | View Filing |
| DEFA14A | 2024-05-29 | 2024-05-29 | View Filing |
| DEFA14A | 2024-05-28 | 2024-05-28 | View Filing |
| 8-K | 2024-05-24 | 2024-05-24 | View Filing |
| DEFA14A | 2024-05-22 | 2024-05-22 | View Filing |
| 8-K | 2024-05-17 | 2024-05-17 | View Filing |
| DEFA14A | 2024-05-17 | 2024-05-17 | View Filing |
| DEFA14A | 2024-05-15 | 2024-05-15 | View Filing |
| 424B3 | 2024-05-10 | 2024-05-10 | View Filing |
| 10-Q | 2024-05-10 | 2024-05-10 | View Filing |
| ARS | 2024-04-29 | 2024-04-29 | View Filing |
| DEF 14A | 2024-04-29 | 2024-04-29 | View Filing |
| 8-K | 2024-04-22 | 2024-04-22 | View Filing |
| PRE 14A | 2024-04-19 | 2024-04-19 | View Filing |
| 424B4 | 2024-04-19 | 2024-04-19 | View Filing |
| EFFECT | 2024-04-17 | 2024-04-17 | View Filing |
| 8-K | 2024-04-03 | 2024-04-03 | View Filing |
| S-1/A | 2024-04-02 | 2024-04-02 | View Filing |
| S-1/A | 2024-03-15 | 2024-03-15 | View Filing |
| 10-K | 2024-03-15 | 2024-03-15 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Buy & Hold | 3,414.20% | 0.97 | 39 | 0.85 | 2.19 | 3414.2 |
| Choppiness Index Strategy | 1,186.27% | 0.7 | 39 | 0.68 | 1.25 | 2227.93 |
| Schaff Trend Cycle Strategy | 693.51% | 0.73 | 34 | 0.61 | 5.91 | 2720.69 |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxxx |
| xxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxxx |
| xxxxxxxxxxxx | xxxxx% | xxxx | x | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | x | xxxx | x | xxxxxx |
| xxxxxxxxxxxxxxxx | xxxxx% | x | x | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxx | xxxxxxx% | xxxx | x | xxxx | xxxxxx | xxxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxx% | xxxx | xx | xxx | xxxx | xxxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxx | xxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxxx | xxxxx |
| xxx | xxxxxxx% | xxxx | x | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxxx |
| xxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxxx |
| xxxxxxxxx | x% | x | x | x | x | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxxx |
| xxx | x% | x | x | x | x | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxxx | xxxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxx% | xxxx | xx | xxxx | xxxxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxx | xxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxxxx |